PT-141 (Bremelanotide) Cardiovascular Impact: Long-Term Safety Data

Bremelanotide, sold under the brand name Vyleesi, is a synthetic cyclic peptide melanocortin receptor agonist. The FDA approved it in June 2019 as a subcutaneous injection for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is often referred to by the research code PT-141, and it is also used off-label, including by some telehealth and compounding channels, for erectile dysfunction in men. This article covers only its cardiovascular effects; it is not a general efficacy or dosing guide.

Bremelanotide is contraindicated in patients with uncontrolled hypertension or established cardiovascular disease, produces a transient blood pressure rise and reflex heart rate drop after each dose that FDA labeling describes as resolving within hours, and has no published cardiovascular outcome data beyond the 52-week RECONNECT extension in the FDA-approved population of premenopausal women with HSDD. No dedicated cardiovascular safety study exists for off-label use in men or for doses above the approved 1.75 mg. Anyone weighing longer-term or off-label use is, by definition, extrapolating beyond the evidence base.

Why does a desire drug affect blood pressure at all?

Bremelanotide's intended therapeutic action is central: it activates melanocortin-4 receptors (MC4R) in the hypothalamus to increase sexual desire. That is separate from a peripheral effect at melanocortin-1 receptors (MC1R) and MC3R on vascular tissue, which is the pathway implicated in the drug's blood pressure and heart rate changes. This dual-receptor pharmacology is why a drug developed for desire carries a cardiovascular warning at all: the peripheral vasoactive effect is a side effect of the same drug class, not an unrelated event.

An earlier intranasal formulation of bremelanotide, tested at higher doses than the current product, produced larger blood pressure increases and was not pursued for approval. The eventual approved product uses a lower dose (1.75 mg) delivered subcutaneously, which narrowed the cardiovascular signal enough for FDA to approve it with a warning and specific contraindications rather than a broader restriction. This history matters for the off-label dosing question addressed below, because dose and route both change the exposure that produced the approved product's safety profile.

What did the approval trials show, and who was in them?

The FDA approval was based on the RECONNECT Phase 3 program, a pooled trial population of premenopausal women with HSDD, followed by a 52-week open-label extension. This is the trial evidence referenced throughout Vyleesi's FDA labeling and the FDA's own drug trials snapshot summary for the product.

Several points about this evidence base matter for interpreting cardiovascular claims:

• The trial population was screened to exclude people with established cardiovascular disease. Safety results describing "no excess of major adverse cardiac events" apply to that pre-screened, comparatively low cardiovascular-risk cohort, not to an unscreened general population.
• FDA's labeling and clinical pharmacology review describe an acute, dose-related rise in blood pressure after subcutaneous dosing that peaks within roughly the first quarter hour and is reported to return toward baseline within about half a day, alongside a modest, transient decrease in heart rate consistent with a reflex (baroreceptor-driven) response rather than direct cardiac suppression. Readers and clinicians who need the exact peak magnitudes in mmHg and beats per minute should confirm the current figures against the FDA label text directly, since this draft treats the numeric specifics as needing verification rather than repeating them as settled to the decimal.
• Nausea was substantially more common with bremelanotide than placebo in the trial program. Because significant nausea can itself provoke a vasovagal response (a separate route to transient blood pressure and heart rate change), it is a secondary, indirect cardiovascular consideration worth asking patients about.
• No excess of major adverse cardiac events (cardiovascular death, non-fatal heart attack, non-fatal stroke) was reported through the 52-week extension in this screened population.

No trial data extend past 52 weeks. No registry study or dedicated post-marketing cardiovascular outcomes trial has been published for bremelanotide. Unlike some other drug classes approved in the same era, FDA did not require a dedicated cardiovascular outcomes trial as a condition of approval. Absence of longer-term data is not evidence that longer-term risk is low; it means the question has not been studied.

Who should not take it, and who needs extra caution?

Contraindicated (per FDA labeling)

• Established cardiovascular disease (coronary artery disease, prior heart attack, prior stroke, peripheral arterial disease)
• Uncontrolled hypertension
• Known hypersensitivity to bremelanotide or product excipients

These are absolute, not relative, contraindications in the approved population. A patient with a cardiac history who wants to use bremelanotide off-label should not do so without explicit cardiology input and shared decision-making, and even then the evidence to guide that decision is thin.

Warrants extra caution, not automatic exclusion

• Controlled hypertension on medication. The label's exclusion is for uncontrolled hypertension. Patients with blood pressure reliably below hypertensive thresholds on stable treatment were not universally excluded from the trial program, but a verified, current blood pressure reading before prescribing is reasonable practice.
• Concurrent vasoactive medications. Triptans, ergot derivatives, decongestants, and stimulant medications are mechanistically plausible candidates for an additive pressor effect. No dedicated interaction study has been published; the caution is based on pharmacologic reasoning, not trial data.
• Bradycardia-prone patients. Because the heart rate effect is a reflex slowing, patients with sick sinus syndrome or those on beta-blockers deserve individualized clinical judgment rather than automatic exclusion.
• Off-label use in men. This deserves its own discussion below because the evidence gap here is structural, not incidental.

The evidence gap in off-label use for men

Bremelanotide's cardiovascular safety data come entirely from a female HSDD population that was screened to exclude cardiovascular disease. Off-label use for erectile dysfunction in men is common in some telehealth and compounding settings, but no dedicated cardiovascular safety trial has been conducted in men. This matters because erectile dysfunction itself is a recognized marker of vascular disease risk in men, meaning the population most likely to seek this off-label use may carry more baseline cardiovascular risk than the population the safety data describe. Anyone prescribing or using bremelanotide off-label for this purpose is extrapolating cardiovascular safety data from a different, lower-baseline-risk population, which is a real limitation, not a formality.

A related, separate gap concerns dose. Compounded products for off-label use sometimes use different doses than the FDA-approved 1.75 mg. Because the vasoactive effect is receptor-mediated and appears dose-related in the record leading to the approved product's dose selection, there is no basis to assume a higher or different dose carries the same, or even a proportionally larger, cardiovascular profile. No data characterize the blood pressure response at doses other than 1.75 mg subcutaneous.

What the FDA label establishes, in plain terms

The FDA label describes bremelanotide as transiently affecting blood pressure and lists uncontrolled hypertension and cardiovascular disease as contraindications. The exact wording of the current label should be confirmed directly from the FDA source before it is quoted verbatim in clinical or patient materials, since label language can be updated and this draft has not independently reproduced it as a verified direct quotation. The FDA prescribing information, the FDA's clinical pharmacology review for the original approval, and the FDA's drug trials snapshot for Vyleesi are the primary regulatory documents for this drug and take precedence over secondary summaries, including this article, whenever they conflict.

Evidence boundary: what is established, what is plausible, what is not known

Established (FDA label and trial program):

• Bremelanotide causes an acute, dose-related rise in blood pressure and a reflex decrease in heart rate after subcutaneous dosing.
• It is contraindicated in uncontrolled hypertension and established cardiovascular disease.
• No excess of major adverse cardiac events was observed through 52 weeks in a cardiovascular-disease-screened trial population.

Plausible but not directly tested:

• Antihypertensive medications likely blunt, without eliminating, the acute blood pressure rise.
• Combining bremelanotide with vasoconstrictive agents (triptans, stimulants) could have an additive pressor effect.
• Higher off-label or compounded doses may produce a larger blood pressure response than the approved dose, based on the dose-response pattern seen during development.

Not established:

• Cardiovascular safety beyond 52 weeks of intermittent use.
• Cardiovascular safety in men using the drug off-label for erectile dysfunction.
• Cardiovascular safety at doses other than the approved 1.75 mg.
• Any effect on long-term measures such as arterial stiffness or coronary calcium, which have not been studied for this drug.

A cardiovascular risk-stratification framework for bremelanotide candidates

This is not a substitute for individualized clinical assessment, and it does not set a dose or diagnose a patient. It organizes the label-based contraindications and the known evidence gaps into a decision structure a clinician or informed patient can use to identify which category applies before deciding on use.

The dividing line that changes what a reader should actually do is not "does bremelanotide raise blood pressure" (it does, acutely, for everyone) but which of these four categories they fall into, since the strength of the underlying safety evidence differs sharply between the approved population and every off-label or extended-duration scenario.

Practical points on monitoring

A clinician considering bremelanotide, on-label or off, would reasonably want a documented baseline blood pressure, a medication and cardiac history focused on vasoconstrictive drugs and prior cardiac events, and a plan for what the patient should do if blood pressure rises or symptoms like chest pain, severe headache, or palpitations occur after a dose. These are standard precautions for any vasoactive medication and are consistent with the label's contraindications; they are not derived from a specific trial-defined monitoring protocol, and any numeric thresholds a clinic uses for home blood pressure checks should be set by the prescribing clinician rather than taken from a general article.

When to seek urgent care

Chest pain, palpitations with lightheadedness, sudden severe headache, or a blood pressure reading a patient's clinician has identified as an emergency threshold after a dose warrant urgent medical evaluation rather than waiting for a routine follow-up. This applies regardless of whether the use is on-label or off-label.

References

1. U.S. Food and Drug Administration. Vyleesi (bremelanotide) prescribing information, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
2. U.S. Food and Drug Administration. Drug Trials Snapshots: Vyleesi, 2019. (link unavailable; consult the FDA's Drug Trials Snapshots database directly)
3. U.S. Food and Drug Administration. Vyleesi, NDA 210557, Clinical Pharmacology Review, 2019. (link unavailable; consult FDA's Drugs@FDA database directly)

While secondary sources discuss the RECONNECT trials and melanocortin receptor pharmacology, the original journal citations for trial-level data in previous versions of this article could not be validated against primary sources and were therefore excluded. Before publication, an editor with access to medical databases should verify and restore the appropriate primary literature citations for these trial outcomes.